Abstract
were not markedly increased (RR for ductal cancer, 1.2; 95% CI, 0.7-2.2 and RR for lobular cancer, 1.3; 95%, CI 0.8-2.4). The RRs for former use (subjects who last used CCBs more than 6 months prior to diagnosis or reference date) were all compatible with 1.0, although there were too few former users to assess duration. The findings were consistent for estrogen receptor–positive and estrogen receptor–negative cancer, for dihydropyridine and non-dihydropyridine CCBs, and for longacting and short-acting CCBs (although there were too few users of the short-acting CCBs for analysis by duration). Given these results, should the use of CCBs be discontinued once a patient has taken them for 9.9 years? The answer is no, because these data are from an observational study, which cannot prove causality and by itself cannot make a case for change in clinical practice. Should the results be dismissed as random noise emanating from an observational
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
